Independent Clinical Laboratories (ICL’s) have been impacted with drastic reimbursement cuts in 2016 and as a result, more than one third of them have been forced to close.
Hospitals continue to endure:
CURRENT STATE
- Reimbursement cuts
- Increases in uncompensated care
- Increases in administrative spending to ensure compliance and guard against inadvertent fraudulence
The seismic shifts within the reimbursement landscapes for both ICL’s and Hospitals have forced the consideration of additional opportunities that create:
- Better economies of scale
- Increased revenue potential
- Cost reductions
- Documented economic/clinical outcomes
